Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
Date:8/8/2013

br>(0.89)Weighted average number of basic and diluted common shares14,673,77114,554,50214,667,24412,394,869Consolidated Balance Sheets(In thousands) June 30,  December 31, 20132012 (unaudited) Assets:  Cash, cash equivalents, short term investments and restricted cash$
57,306$
75,697  Interest receivable300327  Amounts receivable6,439714  Prepaid expenses and other current assets3,5423,755  Property, equipment and other assets1,7211,523Total assets$
9,308$
82,016Liabilities and stockholders' equity:  Accounts payable and accrued liabilities$
,540$
7,050  Current portion of long-term obligations1,0891,084  Warrant liability1,0873,422  Long term liabilities3,9074,253  Stockholders' equity52,68566,207Total liabilities and stockholders' equity$
9,308$
82,016 

 

 

Conference Call Details OncoGenex will host a conference call at 4:30 p.m. Eastern Time today, Thursday, August 8, 2013, to provide a business update and discuss the second quarter 2013 results.

A live event will be available on the Investor Relations section of the OncoGenex website at www.OncoGenex.com. Alternatively, you may access the live conference call by dialing 877-606-1416 (U.S. & Canada) or 707-287-9313 (International). A replay of the webcast will be available approximately two hours after the call and will be archived for 90 days.

ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NYSE:  TEVA)
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. OncoGenex Announces Multiple Trials in Progress Presentations at the 2013 ASCO Annual Meeting
2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
3. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
4. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
5. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
6. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
7. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity Growth Conference
8. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
9. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
10. OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
11. Auxilium Pharmaceuticals, Inc, Announces Second Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015  BiOptix is pleased to ... as Vice President of Chemistry and Biochemistry. Scott joins the ... AstraZeneca Pharmaceuticals, and Amgen throughout the course of his ... "Scott is a nationally recognized thought leader ...
(Date:1/22/2015)...  ResMed Inc. (NYSE: RMD ) today announced results ... quarter was $423.0 million, a 10 percent increase compared to ... on a constant currency basis). Net income was $91.2 million, ... December 31, 2013. Diluted earnings per share for the quarter ...
(Date:1/22/2015)... Jan. 22, 2015  Amgen (NASDAQ: AMGN ) today announced ... financial results on Tuesday, Jan. 27, 2015, after the close of ... conference call with the investment community at 2 p.m. PT. Participating ... , chairman and chief executive officer, and other members of Amgen,s ...
Breaking Medicine Technology:BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... (OTCPK: SNDY) is pleased to announce that the Company ... and sales of its high quality instruments for the ... 2011, Solos Endoscopy consummated agreements, which resulted in the ... The signed settlement agreement and new consulting agreement resulted ...
... Inc. (Nasdaq: MSHL ), an oncology company ... cancer metabolism, announced today that it has reached a ... sell common stock in a private placement for gross ... of the offering, through the sale of approximately 1.94 ...
Cached Medicine Technology:Solos Endoscopy, Inc. is Primed for Growth in 2012 2Solos Endoscopy, Inc. is Primed for Growth in 2012 3Marshall Edwards Adds $2 Million in Private Placement 2Marshall Edwards Adds $2 Million in Private Placement 3
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together ... by up to 30lbs in less than 12 weeks without ... Stevenson, prompting an investigative review. , “Our Incredible Bulk ... formula that allows the body to pack on a massive ...
(Date:1/22/2015)... 2015 AngelWeddingDress, the premier women’s dress ... wedding dresses. View website of AngelWeddingDress.com to ... maternity wedding dresses online for a bridal party. AngelWeddingDress ... quality for them. Its maternity wedding dresses are specially ...
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... effective ways to control weight , , FRIDAY, Dec. 26 (HealthDay ... suppressing appetite, according to a U.K. study. , The ... types of sessions. In one, they ran for 60 minutes ... another, they did 90 minutes of weight lifting and then ...
... Most women expressed satisfaction with process, but long-term data lacking, ... who choose to donate eggs to help infertile couples should ... the first study to examine the long-term effects of donation ... is available to assess whether donating eggs when young has ...
... to date and avoid local dangers, expert advises , , ... sunnier climes this winter, kids in tow? , If ... advises an expert. , "The most common infectious ... of the world may result from exposure to contaminated ...
... basic safety rules should help keep celebrants safe , , ... the holidays, tens of thousands of Americans have to ... injuries and illnesses. That includes about 11,000 people with ... president of the American College of Emergency Physicians. ...
... practice and center for sound sleep in the Midwest is warning ... to a energy-robbing and dangerous disease known as sleep apnea. ... while sleeping. , ... Bloomington, Ind. (PRWEB) December 25, ...
... in children and adolescents should be recognized and treated ... disorders and depression, says a nationally recognized child psychiatrist ... appearing in the Dec. 25 issue of New ... of psychiatry and pediatrics at UT Southwestern, urges awareness ...
Cached Medicine News:Health News:Vigorous Treadmill Workout Curbs Appetite Hormones 2Health News:Risks and Benefits of Egg Donation Reported 2Health News:Risks and Benefits of Egg Donation Reported 3Health News:Consider Kids' Health on Tropical Trips 2Health News:How to Avoid a Holiday Trip to the ER 2Health News:Holiday Weight Gain May Contribute to Sleep Apnea Extra Pounds May Produce Severe Problems for Adults 2Health News:Childhood anxiety disorders can and should be treated, according to UT Southwestern national expert 2
1.5 mm inner cutting edge....
Phaco chopper & iris retractor 2 mm cutting edge....
Round handle dull finish. For right handed surgeon....
Cross action, round handle, maximum opening 2.8 mm....
Medicine Products: